<DOC>
	<DOCNO>NCT00138216</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , vincristine , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose irinotecan give together temozolomide vincristine treat young patient refractory solid tumor .</brief_summary>
	<brief_title>Temozolomide , Vincristine , Irinotecan Treating Young Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose irinotecan administer temozolomide vincristine young patient refractory solid tumor , include brain tumor . - Determine toxic effect regimen patient . - Compare toxic effect regimen patient low- vs high-risk UGT1A1 genotype . - Determine pharmacokinetics irinotecan patient . Secondary - Determine , preliminarily , antitumor activity regimen patient . - Correlate UGT1A1 , UGT1A7 , UGT1A9 , BCRP genotypes pharmacokinetics pharmacodynamics irinotecan metabolite patient . OUTLINE : This multicenter , dose-escalation study irinotecan . Patients stratify accord UGT1A1 genotype ( high-risk [ 7/7 6/7 genotype AND bilirubin ≥ 0.6 mg/dL ] vs low-risk [ absence high-risk criterion ] ) high-risk patient experience dose-limiting toxicity ( DLT ) . Patients receive oral temozolomide day 1-5 oral irinotecan day 1-5 8-12 . Patients also receive vincristine IV 1 minute day 1 8 . Treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . After completion study treatment , patient follow 1 month annually thereafter . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* malignant solid tumor , include brain tumor , original diagnosis relapse Refractory disease NOTE : *Histologic confirmation require intrinsic brain stem tumor Measurable evaluable disease No known curative therapy OR therapy proven prolong survival acceptable quality life exist No known bone marrow metastases PATIENT CHARACTERISTICS : Age 1 21 Performance status Lansky 50100 % ( patient ≤ 10 year age ) Karnofsky 50100 % ( patient &gt; 10 year age ) Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( RBC transfusion allow ) Hepatic ALT ≤ 110 U/L ( upper limit normal [ ULN ] ALT 45 U/L ) Bilirubin ≤ 1.5 time ULN Albumin ≥ 2 g/dL Renal Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( patient ≤ 5 year age ) No great 1.0 mg/dL ( patient 6 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient &gt; 15 year age ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficits patient CNS tumor must stable ≥ 1 week prior study entry No uncontrolled infection No document allergy cephalosporin dacarbazine PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy At least 3 month since prior stem cell transplantation rescue without totalbody irradiation No evidence active graftversushost disease At least 7 day since prior antineoplastic biologic agent At least 7 day since prior hematopoietic growth factor No concurrent biologic therapy immunotherapy No concurrent prophylactic filgrastim ( GCSF ) first course study treatment Chemotherapy Recovered prior chemotherapy Prior temozolomide , vincristine , irinotecan , topotecan allow No prior coadministration temozolomide irinotecan No disease progression treatment either irinotecan temozolomide More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) No concurrent chemotherapy Endocrine therapy Patients CNS tumor must stable decrease dose dexamethasone ≥ 7 day prior study entry Radiotherapy Recovered prior radiotherapy At least 6 month since prior totalbody irradiation , craniospinal radiotherapy , radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) No concurrent radiotherapy Surgery Not specify Other No concurrent investigational drug No concurrent anticancer therapy No concurrent enzymeinducing anticonvulsant , include follow : Phenobarbital Phenytoin Carbamazepine Oxcarbazepine No concurrent administration follow : Rifampin Voriconazole Itraconazole Ketoconazole Aprepitant Hypericum perforatum ( St. John 's wort ) No concurrent treatment clostridium difficile infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
</DOC>